Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) changes shares on Thursday trading session, with a change of -0.32% or -$0.9 shares. The trading starts at $279.40 and closed at $280.09 throughout the day. The trading session low price was $275.93 and day high was $282.2163 on Thursday, June 18. After the session, the Healthcare sector daily volume shifted to 1.36 million while its average volume is 2.18M. In other hand, the VRTX market cap reached to $71.13B. While, its current target price is $279.19 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 5.80% and down -1.09% for month. Its quarterly performance was 29.44% above, while its half year performance is up 28.29%. VRTX yearly performance stood at positive 53.61% and rise 27.51% for year-to-date. Current recommendation for Vertex Pharmaceuticals Incorporated is 1.90.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. VRTX EPS (TTM) for 12-month is 5.76. EPS for this year is 118.10%, while for the next year its value is 10.97. Sales growth for the current quarter is 2.02 while its EPS Q/Q reached 121.50%. It has an EPS of 28.00% up for past five years and for the next five years will be up 23.96%.
Let’s take a look on the analyst recommendations on VRTX for the current month and previous month. For the current month, 20 of 27 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 1 as underweight and 6 as Hold. As compared with the previous month ratings, 27 analysts participate in stock recommendation. Out of 27, 0 rated it sell, 20 rated it as Buy and 7 as Hold Ratings. On the other hand, target price ranges from $245.00-$325.00. Average target price for VRTX was reached at $285.09.
FMR, LLC, Blackrock Inc. and Price (T.Rowe) Associates Inc are the top three holders in Vertex Pharmaceuticals Incorporated (VRTX) stock. On Mar 30, 2020, FMR, LLC has 22.66 million shares which valued 5.39 billion. On Mar 30, 2020, Blackrock Inc. owned 22.33 million shares which valued at 5.31 billion. On Mar 30, 2020, Price (T.Rowe) Associates Inc has a total of 21.62 million shares which valued at 5.15 billion. In the end, Price (T.Rowe) Associates Inc have 8.34% shares outstanding of Vertex Pharmaceuticals Incorporated (VRTX) on Mar 30, 2020. The insider ownership moved to 0.10% and institutional holding shifted to 97.10%.
The company posted an EPS (TTM) of 5.76. According to the most recent quarter report on (Jun 2020), 18 analysts estimated an average EPS of 2.04, while 1.26 EPS posted a year ago period. Analyst Estimated EPS for VRTX published in the report was 1.51-2.35 during the same period. Comparing with last year, the average estimated EPS was 1.26 which is lower than 2.56 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for VRTX rise 23.71% for period of 200 days. SMA for 50 days was 3.33% which is showing green signal, while SMA-20 was 1.24%. The moving average value for Vertex Pharmaceuticals Incorporated (VRTX) is 243.21 and 274.06 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in VRTX stock. On Jun 02, Bhatia Sangeeta N., Director, sold 952 trading shares at the cost of $282.88, which valued at 0.27 million. On May 15, Kewalramani Reshma, CEO & President, sold 99 shares at the cost of $284.17, with total shares of 26,626. On May 15, Tatsis Ourania, EVP, Chief Regulatory Officer, sold 120 shares at the cost of 284.00. After this transaction, Tatsis Ourania total shares reached to 12,738 which valued at 34080.0.